Conclusions This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first [vaccine] group.
https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1